Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 9 | 2024 | 130 | 2.600 |
Why?
|
| Pharmacy | 8 | 2023 | 17 | 2.570 |
Why?
|
| Pharmacies | 8 | 2023 | 36 | 1.850 |
Why?
|
| Students, Pharmacy | 4 | 2024 | 12 | 1.750 |
Why?
|
| Education, Pharmacy | 3 | 2024 | 17 | 1.560 |
Why?
|
| Pharmacy Research | 4 | 2024 | 4 | 1.430 |
Why?
|
| Licensure, Pharmacy | 2 | 2024 | 2 | 1.060 |
Why?
|
| Educational Measurement | 3 | 2024 | 213 | 1.050 |
Why?
|
| Accreditation | 1 | 2024 | 76 | 0.820 |
Why?
|
| Contraceptive Devices, Female | 1 | 2023 | 2 | 0.810 |
Why?
|
| Pharmaceutical Services | 2 | 2023 | 33 | 0.810 |
Why?
|
| Contraceptive Agents, Female | 1 | 2023 | 24 | 0.790 |
Why?
|
| Pharmacy Service, Hospital | 4 | 2023 | 21 | 0.770 |
Why?
|
| Social Media | 1 | 2024 | 128 | 0.700 |
Why?
|
| Prescription Drugs | 1 | 2020 | 49 | 0.630 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 106 | 0.600 |
Why?
|
| Surveys and Questionnaires | 6 | 2025 | 2759 | 0.570 |
Why?
|
| Drug Industry | 1 | 2018 | 41 | 0.540 |
Why?
|
| Naloxone | 1 | 2018 | 53 | 0.530 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 133 | 0.490 |
Why?
|
| Program Evaluation | 1 | 2018 | 488 | 0.470 |
Why?
|
| Medicare Part C | 1 | 2015 | 14 | 0.470 |
Why?
|
| House Calls | 1 | 2015 | 23 | 0.460 |
Why?
|
| Community Pharmacy Services | 3 | 2022 | 12 | 0.450 |
Why?
|
| Buprenorphine | 1 | 2018 | 198 | 0.430 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 50 | 0.430 |
Why?
|
| Anticonvulsants | 1 | 2014 | 103 | 0.410 |
Why?
|
| United States | 7 | 2024 | 8082 | 0.410 |
Why?
|
| Curriculum | 1 | 2018 | 607 | 0.410 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 526 | 0.400 |
Why?
|
| Epilepsy | 1 | 2014 | 113 | 0.400 |
Why?
|
| Health Communication | 1 | 2013 | 33 | 0.400 |
Why?
|
| Insurance, Health | 1 | 2014 | 151 | 0.390 |
Why?
|
| Humans | 25 | 2025 | 64934 | 0.370 |
Why?
|
| Patient Readmission | 1 | 2015 | 446 | 0.350 |
Why?
|
| Drugs, Generic | 2 | 2020 | 19 | 0.330 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 526 | 0.320 |
Why?
|
| Drug Costs | 2 | 2020 | 55 | 0.320 |
Why?
|
| Internet | 1 | 2013 | 466 | 0.320 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6840 | 0.290 |
Why?
|
| Schools, Pharmacy | 2 | 2024 | 7 | 0.260 |
Why?
|
| Contraception | 2 | 2023 | 72 | 0.230 |
Why?
|
| Intention | 1 | 2025 | 73 | 0.220 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 69 | 0.210 |
Why?
|
| North America | 1 | 2024 | 113 | 0.210 |
Why?
|
| Bibliometrics | 1 | 2024 | 35 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 133 | 0.200 |
Why?
|
| Spain | 4 | 2023 | 32 | 0.200 |
Why?
|
| Publishing | 1 | 2024 | 95 | 0.190 |
Why?
|
| Vaccination | 1 | 2025 | 375 | 0.190 |
Why?
|
| Female | 11 | 2025 | 33915 | 0.190 |
Why?
|
| Medicine | 1 | 2023 | 55 | 0.180 |
Why?
|
| Universities | 1 | 2023 | 168 | 0.180 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2022 | 36 | 0.180 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 178 | 0.170 |
Why?
|
| Urinary Tract | 1 | 2020 | 11 | 0.160 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 12 | 0.160 |
Why?
|
| Dexmedetomidine | 1 | 2020 | 10 | 0.160 |
Why?
|
| Anesthetics, Intravenous | 1 | 2020 | 25 | 0.160 |
Why?
|
| Propofol | 1 | 2020 | 21 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 496 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 66 | 0.160 |
Why?
|
| Professional Role | 2 | 2022 | 45 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 132 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2020 | 126 | 0.150 |
Why?
|
| Medication Therapy Management | 2 | 2019 | 18 | 0.150 |
Why?
|
| Patient Care | 1 | 2020 | 76 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2020 | 179 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2020 | 232 | 0.140 |
Why?
|
| Middle Aged | 6 | 2025 | 18203 | 0.140 |
Why?
|
| Young Adult | 3 | 2023 | 4793 | 0.140 |
Why?
|
| Male | 9 | 2025 | 30942 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2020 | 350 | 0.140 |
Why?
|
| Adult | 5 | 2025 | 17306 | 0.130 |
Why?
|
| Massachusetts | 1 | 2023 | 2141 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 105 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 406 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 400 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2018 | 199 | 0.120 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 14 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 795 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1224 | 0.100 |
Why?
|
| Texas | 1 | 2013 | 59 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 195 | 0.100 |
Why?
|
| Medicaid | 1 | 2018 | 370 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 60 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 5600 | 0.100 |
Why?
|
| Electronic Mail | 1 | 2013 | 46 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 164 | 0.100 |
Why?
|
| Aged | 4 | 2022 | 14917 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2701 | 0.100 |
Why?
|
| Professional-Patient Relations | 1 | 2013 | 126 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 655 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 181 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2020 | 1551 | 0.090 |
Why?
|
| Text Messaging | 1 | 2013 | 97 | 0.090 |
Why?
|
| Mutation | 1 | 2020 | 2657 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 1113 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2014 | 881 | 0.080 |
Why?
|
| Prevalence | 1 | 2014 | 1439 | 0.080 |
Why?
|
| Adolescent | 1 | 2014 | 6292 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2022 | 49 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2022 | 9 | 0.050 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 12 | 0.050 |
Why?
|
| Half-Life | 1 | 2022 | 81 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 135 | 0.040 |
Why?
|
| Focus Groups | 1 | 2023 | 319 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 206 | 0.040 |
Why?
|
| Amphibian Proteins | 1 | 2020 | 9 | 0.040 |
Why?
|
| Xenopus | 1 | 2020 | 55 | 0.040 |
Why?
|
| Motivation | 1 | 2023 | 294 | 0.040 |
Why?
|
| Morpholinos | 1 | 2020 | 52 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 767 | 0.040 |
Why?
|
| Pedigree | 1 | 2020 | 193 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 157 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 173 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 122 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 316 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 133 | 0.040 |
Why?
|
| Family | 1 | 2020 | 245 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 296 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1138 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 625 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 825 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1639 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 2152 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 2052 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2371 | 0.030 |
Why?
|
| New England | 1 | 2015 | 270 | 0.030 |
Why?
|
| Child | 1 | 2020 | 4606 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 11085 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 21286 | 0.010 |
Why?
|